Navigation Links
Arsenal Capital Partners Acquires Leading Model-Based Drug Development Company Certara
Date:12/19/2013

NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Arsenal Capital Partners, a leading New York-based private equity firm that invests in middle market healthcare and specialty industrial companies, announced today the acquisition of Certara, the leading provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.Certara provides highly specialized and integrated solutions which consist of computer-based models supported by leading scientific consulting services and which span the discovery, pre-clinical and clinical stages of drug development. Certara's solutions provide clients with significant reductions in the time and expense of bringing new drugs to market by enabling data-driven decisions which lead to more precisely designed studies with less risk of failure and improved subject safety– a benefit in the highly-regulated and increasingly costly research and development environment.

Stephen McLean, a Partner at Arsenal and Co-Head of the firm's Healthcare Group, said, "We are delighted to invest in this exciting company which is making such an important contribution to improving the productivity of the drug development process. The average cost today of researching and developing a new drug is over $1.5 billion and takes 10-15 years. This is clearly inconsistent with the imperative of reducing the costs of global healthcare and Certara will make a difference."

Dr. James Rothman, a recipient of the 2013 Nobel Prize in Physiology or Medicine, who evaluated the Certara acquisition in his role in Arsenal Capital Partners' Healthcare Group, said Arsenal was interested in the acquisition because of Certara's ability to increase both the effectiveness and efficiency of the drug development process. "Model-based drug development is allowing pharmaceutic
'/>"/>

SOURCE Arsenal Capital Partners
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
2. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
3. TVM Capital Group Announces Two-pronged Global Investment Strategy with Renewed MENA Focus
4. Foundation Venture Capital Group Portfolio Company Identifies FRY Gene As Breast Cancer Susceptibility Suppressor
5. S&P Capital IQ to Share Its Views on the Biotech Bull Market During the Next "ETF Analyst Hour"
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
8. GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
9. Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
10. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
11. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Nine field days to promote ... Indiana. Hosted by the Soil Health Partnership , the field days will demonstrate ... while potentially increasing farm productivity and income. , Brent Bible has practiced no-till farming ...
(Date:8/3/2015)... , Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences ... company focused on the development of autologous cell therapies, announced ... presenting at the InvestMNT conference held in Minneapolis, ... AM local time. Hall,s presentation will highlight RepliCel,s 18-month milestones ... in Europe , clinical data from both ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report ... the current state of the global Propanol market with a focus on the Chinese ... Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... Recent action in Congress to reauthorize the U.S. ... address the social and ethical issues concerning the ... to address social and ethical issues now as ... nanotechnology and its possible significant contributions to our ...
... N.J., Jan. 27 Alfacell Corporation (OTC Bulletin Board: ... meeting with the U.S. Food and Drug Administration (FDA) ... components of the ONCONASE rolling New Drug Application (NDA) ... At the pre-NDA meeting, the FDA provided guidance ...
... Efficacy and Excellent TolerabilityCORONA, Calif., Jan. 27 Watson ... in generic and specialty branded pharmaceuticals, announced today that ... GELNIQUE(TM) (oxybutynin chloride) Gel 10%, the first and only ... with symptoms of urge urinary incontinence, urgency, and frequency. ...
Cached Biology Technology:Ethical evaluations of nanotechnology 2Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 2Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 4
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... growing concerns about the spread of harmful mercury in plants ... Hopkins University and The National Aquarium has compared levels of ... wild. The captive animals were fed a controlled diet, while ... more of the toxic metal., The study found lower levels ...
... their hunting sequence - capture, handling and consumption - to ... ones they are better off leaving alone or dropping mid-way ... then they assess its size, and finally they taste it. ... the Smithsonian Tropical Research Institute in Panama is published online ...
... multi-university study reports that differences in bacterial colonization of the ... in the expression of genes involved in the infant,s immune ... of BioMed Central,s open access journal Genome Biology , ... of University of Illinois, Texas A&M University, Miami University, and ...
Cached Biology News:Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 2Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 3What sounds good doesn't always taste good 2Breast-fed babies' gut microbes contribute to healthy immune systems 2
Compact, portable device, seals 96 and 384 well plates with preset temperature optimised for Eppendorf heat sealing foils and films. Suitable for plates of different heights. AC input: 50/60 Hz230 V...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
... Proteins (TBP). Ascites Antibody ITBP20 was raised ... acids 41-57 and may be useful in ... This antibody does not inhibit the ... nuclear extract or as a minimal activity ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: